ASMS 2024 -- According to Verified Market Research, at-home microsampling blood collection market size was valued at USD 8.9 billion in 2021 and is projected to reach USD 13.2 billion by 2027, growing at a CAGR of 5.1% from 2022 to 2030 (Jersey City, NJ, Aug. 17, 2022).
ESTIV Congress 2024 -- Tumour formation is a multi-stage process including an initiation stage (genomic level) and a promotion stage (cellular level). If required for regulatory submissions, the gold-standard method assay for carcinogenicity potential is the 2-year rodent carcinogenicity assay.
Explore tissue heterogeneity and the complexity of microenvironments with GeoMx� Digital Spatial Profiler (DSP). GeoMx DSP offers a more comprehensive and nuanced understanding of biological systems compared to conventional bulk RNA analysis. The tumor microenvironment (TME) is heterogeneous, containing numerous components in spatially distinct areas.
Introducing Labcorp Global Trial Connect. Complementary digital, data and operational solutions to enable sites to spend more time with their patients, get studies started faster, maintain study momentum and increase study throughput.
Minimize delays by tightly controlling this pre-submission timeline. Talk to your chosen eCA early on to arrange a pre-submission meeting; some eCAs are open to receiving final long-term stability data after submission if this is agreed before submission, significantly shortening the timeline.
STP 2024 -- Historically, the use of two-year rodent (CD-1� mouse and Sprague Dawley� or Wistar Han� rat) studies has been the standard practice to assess the carcinogenic potential of pharmaceuticals.
STP 2024 -- Carcinogenicity studies are important in identifying tumorigenic potential in animals as part of the risk assessment for new drugs. Historical control incidences are important considerations when interpreting data and useful when selecting and assessing the suitability of an animal model.
STP 2024 -- Compounded formulations of buprenorphine HCl extended-release polymer injection solution (BUP-ER) offer convenient, long-acting pain control for laboratory animals. Several long-acting buprenorphine formulations have recently been reported to cause significant injection site reactions in nonhuman primates and rodents.
While designing a qPCR/ddPCR assay for supporting cell and gene therapies can be straight forward, there are also key challenges and complexities molecular bioanalytical scientists currently face in the process.
